Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

@article{Cheson2006ClinicalAA,
  title={Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.},
  author={Bruce D Cheson and Peter L. Greenberg and John M. Bennett and Bob Lowenberg and Pierre W. Wijermans and Stephen D. Nimer and Antonio Pinto and M. Beran and Theo J M de Witte and Richard M. Stone and Moshe Mittelman and Guillermo F. Sanz and Steven D Gore and Charles A Schiffer and Hagop M. Kantarjian},
  journal={Blood},
  year={2006},
  volume={108 2},
  pages={
          419-25
        }
}
The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment. Therapeutic trials in MDS have used various criteria to assess results, making cross-study comparisons problematic. In 2000, an International Working Group (IWG) proposed standardized response criteria for evaluating clinically significant responses in MDS. These criteria… 
View on PubMed
adelphigroup.com
1,234 Citations
Highly Influential Citations
64
Background Citations
144
Methods Citations
356
Results Citations
7

1,234 Citations

Citation Type

Citation Type

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.
The heterogeneity of myelodysplastic syndromes (MDSs) has made evaluating patient response to treatment challenging. In 2006, the International Working Group (IWG) proposed a revision to previously…
Meaningful response criteria for myelodysplastic syndromes
TLDR
A critical analysis of the current MDS response criteria is presented from both a practical standpoint and based on currently available clinical trial data, highlighting potential areas for improvement.
Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
TLDR
CR by IWG 2006 response criteria can be used as a surrogate endpoint for OS in higher‐risk MDS pts and any response associated with restoration of effective hematopoiesis is associated with better outcome.
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
TLDR
This work proposes response assessment guidelines to harmonize future clinical trials with the principal objective of establishing suitable treatment algorithms for MDS/MPN.
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
TLDR
An international panel of experts recently convened and delineated 3 response categories: complete remission (CR), partial remission (PR), and clinical improvement (CI).
Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine
TLDR
Azacitidine showed similar efficacy in all patient groups, even in patients with poor cytogenetics and in high-risk groups, and the achievement of HR was associated with a significant increase in OS.
Development of a core outcome set for myelodysplastic syndromes – a Delphi study from the EUMDS Registry Group
TLDR
The first MDS core outcome set (MDS‐COS) defining a minimum set of outcomes that should be reported in future clinical studies is developed to enhance comparability across future MDS studies and facilitate a better understanding of treatment effectiveness.
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.
TLDR
Clinical trialists designing studies struggle with several important trial design challenges, including which patients constitute the "previously treated" and "relapsed/refractory" MDS populations, and how specifically to define disease progression.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Report of an international working group to standardize response criteria for myelodysplastic syndromes.
TLDR
An international working group of experienced clinicians involved in the management of patients with MDS reviewed currently used response definitions and developed a uniform set of guidelines for future clinical trials in MDS, aimed at improving communication among investigators and to ensure comparability among clinical trials.
Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.
TLDR
Reanalysis of the response rates using IWG criteria demonstrate consistent results across three sequential studies and further validate the superiority of azacitidine over supportive care alone.
International scoring system for evaluating prognosis in myelodysplastic syndromes.
TLDR
Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS and should prove useful for more precise design and analysis of therapeutic trials in this disease.
Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan.
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
TLDR
An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials.
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
TLDR
Aza C treatment results in significantly higher response rates, improved quality of life, reduced risk of leukemic transformation, and improved survival compared with supportive care.
Drug Insight: emerging new drugs in the treatment of myelodysplastic syndromes
TLDR
Novel and targeted therapeutic agents, including inhibitors of farnesyltransferases and receptor tyrosine kinases, more potent thalidomide analogs and epigenetic therapies, have produced encouraging results and might offer durable benefits to patients with MDS.
European Multi-Centre Study on the Use of Anti-Thymocyte Globulin in the Treatment of Myelodysplastic Syndromes.
TLDR
A single course of ATG can induce durable haematological responses in a significant proportion of patients with MDS, with improved overall survival, and should be considered as a treatment option in patients with low IPSS.
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.
TLDR
It was concluded that thalidomide, as a single agent, is effective in improving cytopenias of some MDS patients, especially those who present without excess blasts.
High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRATM).
TLDR
In a large cohort of pt with high-risk MDS as defined by FAB and IPSS, clinical activity with durable responses and limited toxicity is confirmed for R115777.
...
1
2
3
4
5
...